Dermata Therapeutics, Inc.(DRMA)

Biotechnology · San Diego, CA

$1.13+0.02 (+1.80%)

Delayed quote: Oct 6, 2026, 2:56 PM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T19:11:32.873Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:11:32.873Z.

Quote observation: 2026-10-06T18:56:03.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,545,022
TTM operating cash flow · period ending 2026-06-30: -8,034,258

FMP input reference: 7afec7845e5c1de7d6a7da79415c7f2016586588c7dc262303e5dc1b6d25f1da

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DRMA Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

DRMA Competitors' Price/OCF Ratio

DRMA

Dermata Therapeutics, Inc.

Current

Market Cap

$4.55M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CALC

CalciMedica, Inc.

vs DRMA

Market Cap

$4.66M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMCB

PharmaCyte Biotech, Inc.

vs DRMA

Market Cap

$4.53M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLGN

CollPlant Biotechnologies Ltd.

vs DRMA

Market Cap

$4.27M

Price/OCF Ratio

N/A

TTM Avg

35.59

3Y Avg

35.59

5Y Avg

35.59

XBIO

Xenetic Biosciences, Inc.

vs DRMA

Market Cap

$4.81M

Price/OCF Ratio

N/A

TTM Avg

11.16

3Y Avg

11.16

5Y Avg

11.16

BGMS

Bio Green Med Solution, Inc.

vs DRMA

Market Cap

$4.68M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIDX

20/20 Biolabs Inc.

vs DRMA

Market Cap

$4.23M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LEXX

Lexaria Bioscience Corp.

vs DRMA

Market Cap

$5.03M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PCSA

Processa Pharmaceuticals, Inc.

vs DRMA

Market Cap

$4.11M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GRI

GRI Bio, Inc.

vs DRMA

Market Cap

$4.11M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Dermata Therapeutics, Inc. (DRMA)	$4.55M	N/A	N/A	N/A	N/A
CalciMedica, Inc. (CALC)vs ›	$4.66M	N/A	N/A	N/A	N/A
PharmaCyte Biotech, Inc. (PMCB)vs ›	$4.53M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.27M	N/A	35.59	35.59	35.59
Xenetic Biosciences, Inc. (XBIO)vs ›	$4.81M	N/A	11.16	11.16	11.16
Bio Green Med Solution, Inc. (BGMS)vs ›	$4.68M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.23M	N/A	N/A	N/A	N/A
Lexaria Bioscience Corp. (LEXX)vs ›	$5.03M	N/A	N/A	N/A	N/A
Processa Pharmaceuticals, Inc. (PCSA)vs ›	$4.11M	N/A	N/A	N/A	N/A
GRI Bio, Inc. (GRI)vs ›	$4.11M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

DRMA Price/OCF Ratio Metrics

DRMA Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics